Skip to content
10-Q

Quarterly Report

MiNK Therapeutics, Inc. INKT

0000950170-25-072789

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 12, 2025 3.99M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $3.23M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $4.58M
Current Liabilities Q1 2025 · Mar 31, 2025 $12.12M
Current Liabilities Q1 2025 · Dec 31, 2024 $6.96M
Current Assets Q1 2025 · Mar 31, 2025 $3.58M
Current Assets Q1 2025 · Dec 31, 2024 $4.99M
Total Assets Q1 2025 · Mar 31, 2025 $4.27M
Total Assets Q1 2025 · Dec 31, 2024 $5.72M
Shares Diluted restated Q1 2025 · Mar 31, 2024 3.46M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$2.54M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$20.3M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$18.06M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$1.10
Eps Basic restated Q1 2025 · Mar 31, 2024 −$1.10
Sga Expense Q1 2025 · Mar 31, 2024 $1.28M
Rd Expense Q1 2025 · Mar 31, 2024 $2.55M
Net Income Q1 2025 · Mar 31, 2024 −$3.81M
Operating Income Q1 2025 · Mar 31, 2024 −$3.83M